The development of a series of novel 7-azabenzofurans exhibiting pan-genotype inhibition of HCV NS5B polymerase primer grip will be discussed. Many challenges including poor oral bioavailability, high clearance, bioactivation, high human serum shift, and metabolic stability were overcome through SAR studies. This work culminated in the discovery of a preclinical candidate and a structurally differentiated backup compound.

Discovery of a pan-genotype HCV NS5B polymerase primer grip inhibitor

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.